Stockwinners Market Radar for November 20, 2024 - Earnings, Upgrades downgrades, option trades, Best Stock Advisory Service

20:03 EST Cathie Wood's ARK Investment buys 383K shares of Recursion Pharmaceuticals today

19:50 EST Luminar Technologies trading halted, news pending

19:22 EST Jazz Pharmaceuticals announces FDA approval of Ziihera in BTC - Jazz Pharmaceuticals "announced the U.S. Food and Drug Administration accelerated approval of Ziihera 50mg/mL for injection for intravenous use for the treatment of adults with previously treated, unresectable or metastatic HER2-positive (IHC 3+) biliary tract cancer, or BTC, as detected by an FDA-approved test.1 Ziihera was approved under accelerated approval based on a 52% objective response rate and a median duration of response of 14.9 months as determined by independent central review. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial.1 The Phase 3 HERIZON-BTC-302 confirmatory trial is ongoing to evaluate zanidatamab in combination with standard-of-care therapy versus standard-of-care therapy alone in the first-line setting for patients with HER2-positive BTC. The FDA approval of Ziihera is based on compelling data from the HERIZON-BTC-01 trial, which included the evaluation of zanidatamab as a single agent in previously treated HER2-positive BTC and is the largest Phase 2b clinical trial to date specifically for this patient population. The trial achieved its primary endpoint of confirmed objective response rate by independent central review and results were presented at the American Society of Clinical Oncology Annual Meeting 2023, published in The Lancet Oncology, and included in the 2023 Best of ASCO(R) program. Longer follow-up data showing improvement upon previously reported DOR were reported at the ASCO Annual Meeting 2024."

19:02 EST Sweetgreen director sells $1.63M in common stock - In a regulatory filing, Sweetgreen disclosed that its director Bradley Singer sold 42.7K shares of common stock on November 20th in a total transaction size of $1.63M.

18:37 EST Palo Alto Networks CEO: We are seeing strong demand across the board - In an interview on CNBC's Mad Money, Nikesh Arora said Palo Alto Networks (PANW) is the premium platform with cloud security. The company continues to take market share and it's sticky, with no churn, he added. The partnership with IBM (IBM) portends good business in the future, he noted. There has never had a billion dollar pipeline between the two companies, according to Arora. He expects to see increased investment from the government as it has a lot of legacy systems that need to upgraded.

17:44 EST Nvidia sees Q4 gaming revenue down sequentially due to supply constraints - Says another record was achieved in data center. Says racing to scale Blackwell supply to the incredible demand customers are placing. Says expects market in China to remain very competitive. Says Q4 gaming revenue to decline sequentially due to supply constraints. Says will ship more Blackwells next quarter than this quarter. Says there are no companies that are not going to do machine learning. Says many AI services are running 24/7. Says could potentially reach mid 70s gross margin in the back half of next year. Says has seen substantial growth for H200. Comments and guidance taken from Q3 earnings conference call.

17:18 EST Dream Finders Homes to replace Haynes in S&P 600 at open on 11/25 - Haynes International is being acquired in a deal expected to close soon pending final closing conditions.

17:13 EST Beyond provides update on securities transaction with Container Store - Beyond (BYON) provided an update regarding the proposed financing arrangements for its pending transaction with Container Store (TCS). When Beyond entered into the Securities Purchase Agreement dated October 15, the parties agreed that Container Store would secure new financing on terms commercially acceptable to Beyond as a condition to closing. Given the importance of The Container Store establishing a sustainable capital structure, Beyond negotiated for and obtained a right to determine, in its sole discretion, the adequacy of The Container Store's financing arrangements. Based on the financing proposal presented to date, Beyond has concerns regarding The Container Store's ability to reach agreement with lenders on terms that would satisfy the financing requirements under the Purchase Agreement. Beyond will continue to evaluate any financing proposals The Container Store may provide to Beyond. However, if The Container Store is unable to obtain commercially acceptable financing as set forth in the Purchase Agreement by January 31, 2025, then either party may terminate the Purchase Agreement.

17:06 EST SCWorx announces compliance with Nasdaq's listing standard - SCWorx Corp. announced that it has regained compliance with The Nasdaq Stock Market's continued listing requirements regarding periodic reporting. On April 17, May 17, and August 19, 2024, Nasdaq notified the company that it no longer met the Nasdaq's periodic filing requirement under Listing Rule 5250(c)(1). In a letter dated October 14, 2024, Nasdaq indicated that based on the September 24, October 10, and October 11, 2024, filing of the company's Form 10-K for the year ended December 31, 2023, and Forms 10-Q for the periods ended March 31, and June 30, 2024, respectively, Staff had determined that the company complies with the Rule and that the matter was now closed.

17:03 EST Waldencast up 10% at $3.74 after Q3 results

17:00 EST Reddit reports issues, outage - "Investigating: We are currently investigating this issue.," said company in an X post earlier..Reference Link

16:54 EST Innodata director Toor sells 160,000 common shares - In a regulatory filing, Innodata director Nauman Sabeeh Toor disclosed the sale of 160,000 common shares of the company on November 19 at a price of $44.91 per share.

16:41 EST Reinsurance Group announces $4.1B coinsurance transaction with Manulife Financial - Reinsurance Group (RGA) and John Hancock, a subsidiary of Manulife Financial (MFC), an international financial services group, announced an agreement to reinsure approximately $4.1B in liabilities comprising $1.9B in long-term care, or LTC, and $2.2B in structured settlements. This latest transaction builds on RGA's long-standing strategic partnership with Manulife across a wide range of business types and global markets. The reinsured LTC block consists of policies that closely match the characteristics of RGA's current in-force LTC portfolio, including that all such policies were issued in 2007 or later. The structured settlements block highlights the power of RGA's expertise in longevity risk and the company's 25-year history as a premier provider of asset-intensive solutions. Both transactions are on a full-risk basis, with RGA coinsuring 75% quota share. RGA will also continue supporting John Hancock on their expected growth in U.S. permanent life business through partnership on yearly renewable term reinsurance, at market terms.

16:35 EST Manulife Financial announces C$5.4B reinsurance transaction with RGA - Manulife Financial announced that it has entered into a C$5.4B reinsurance agreement with Reinsurance Group of America, including C$2.4B of long-term care reserves. Key highlights of the transaction: "Reinsuring C$2.4B of LTC reserves to RGA on a full risk transfer basis. Inclusive of our previous LTC reinsurance transaction, upon closing we will have cumulatively reduced LTC reserves by 18% and LTC morbidity sensitivity by 17%. Transacted LTC block is younger, with a greater proportion of active life reserves than our previous transaction. Modest negative 4% LTC cede further validates our reserves and assumptions. Transaction also includes a legacy block of U.S. structured settlements with C$3B of reserves. Accretive to core ROE, and an attractive core earnings multiple of 11.4 times; neutral impact to core EPS. Close to 1.0x book value; expect to release C$0.8B of capital, which we intend to fully return to shareholders. Expect to dispose C$1.5B of alternative long-duration assets." Roy Gori, Manulife President & Chief Executive Officer said, "We are further unlocking significant shareholder value with a second milestone LTC reinsurance transaction within 12 months, which accelerates our transformation to reshape our portfolio towards higher return and lower risk. This transaction further demonstrates our ability to execute on complex transactions and collaborate with experienced counterparties to deliver win-win outcomes, including on both mature and younger LTC blocks. The deal is priced at 11.4 times core earnings multiple and is expected to be accretive to core ROE after we return the released capital to shareholders through share buybacks."

16:31 EST Nvidia CFO sees Blackwell demand to exceed supply for 'several quarters' in FY26 - Nvidia's CFO stated: "We completed a successful mask change for Blackwell, our next Data Center architecture, that improved production yields. Blackwell production shipments are scheduled to begin in the fourth quarter of fiscal 2025 and will continue to ramp into fiscal 2026. We will be shipping both Hopper and Blackwell systems in the fourth quarter of fiscal 2025 and beyond. Both Hopper and Blackwell systems have certain supply constraints, and the demand for Blackwell is expected to exceed supply for several quarters in fiscal 2026."

16:28 EST Raymond James reports October assets under administration $241.1B - "Client assets under administration grew 25% year-over-year but declined 2% compared to the preceding month primarily due to lower equity markets in October. The previously announced departure of predominantly one large independent branch negatively affected asset levels as of month end, despite strong recruiting and retention," said Chair and CEO Paul Reilly. "Clients' domestic cash sweep and Enhanced Savings Program balances ended the month relatively unchanged, as inflows offset quarterly fee billings. Our investment banking pipeline and activity levels are healthy."

16:27 EST Nvidia reports Q3 Gaming revenue $3.3B, up 15% from last year - Nvidia reports Q3 Gaming revenue was $3.3B, up 14% from the previous quarter and up 15% from a year ago.

16:22 EST Matthews increases quarterly dividend to 25c per share - Matthews International Corporation announced that its Board of Directors declared, at its regularly scheduled meeting a dividend of 25c per share on the Company's common stock, representing an increase to the Company's quarterly dividend rate.Joseph C. Bartolacci, President and Chief Executive Officer, stated: "Consistent with our long-term practice, we are pleased to announce another annual increase in our dividend for fiscal 2025. This reflects our ongoing confidence in the Company's cash generation and long-term growth strategies." This represents the 31st consecutive annual dividend increase since becoming a publicly-traded company.The dividend is payable December 16 to stockholders of record December 2.

16:21 EST First US Bancshares expands share repurchase program - First US Bancshares has expanded the company's existing share repurchase program. The company has repurchased 1,289,972 shares of its common stock to date under the repurchase program, and 352,813 shares remain available for repurchase. The board has authorized the company to repurchase an additional 600,000 shares under the repurchase program and extended the expiration of the repurchase program from December 31, 2024, to December 31, 2025.

16:19 EST Applied Optoelectronics files patent infringement claim against Eoptolink - Applied Optoelectronics announced that it has filed a complaint for patent infringement against Eoptolink Technology in the U.S. District Court for the Northern District of California, Case No.: 3:24-cv-08165. The complaint, filed November 19, in the U.S. District Court for the Northern District of California, alleges that at least the Eoptolink 400G QSFP-DD LR4, Eoptolink 400G QSFP-DD FR4, Eoptolink 400G QSFP-DD DR4, Eoptolink 100G QSFP28 LR4, Eoptolink 100G QSFP28 DR1+, and Eoptolink 100G QSFP28 CWDM4, infringe one or more of the asserted of Applied Optoelectronic optical transceiver patents. In the complaint, AOI is seeking monetary damages from Eoptolink and a permanent injunction.

16:17 EST Pyxis Oncology announces preliminary PYX-201 data, collaboration with Merck - Pyxis Oncology (PYXS) announced preliminary data from the ongoing Phase 1 clinical dose escalation study evaluating PYX-201 in multiple types of solid tumors. PYX-201, the company's lead clinical drug candidate, is a first-in-concept antibody-drug conjugate with a microtubule inhibitor payload that uniquely targets Extradomain-B Fibronectin, a non-cellular structural component within the tumor extracellular matrix. Significant clinical responses were observed in HNSCC. Among evaluable HNSCC patients treated at an identified dose range of PYX-201 from 3.6 - 5.4 mg/kg, a confirmed 50% objective response rate, or ORR, was observed, including one confirmed complete response, or CR, and two confirmed partial responses, or PR, by RECIST 1.1. The company additionally announces that it has entered into a clinical trial collaboration agreement with Merck (MRK) for a Pyxis Oncology-sponsored study of PYX-201 in combination with Merck's anti-PD-1 therapy, Keytruda in patients with 1L and 2L head and neck squamous cell carcinoma, HR+/HER2- breast cancer, and triple-negative breast cancer and sarcoma. The company expects to initiate the following HNSCC Phase 1 expansion studies: PYX-201 and Keytruda combination dose escalation and expansion study in 1L and 2L HNSCC with preliminary clinical data readout expected in the second half of 2025; PYX-201 monotherapy study in 2L and 3L HNSCC patients who are platinum and PD-1 inhibitor experienced, with preliminary clinical data readout expected in the second half of 2025 and PYX-201 monotherapy study in 2L and 3L HNSCC patients who are EGFR and PD-1 inhibitor experienced, with preliminary clinical data readout expected in first half of 2026. Exploratory PYX-201 Phase 1 monotherapy expansion cohorts are planned in ovarian cancer, NSCLC, HR+/HER2- breast cancer, TNBC, and sarcoma, with preliminary clinical data expected in the second half of 2025. PYX-201 and Keytruda combination study in HR+/HER2- breast cancer, TNBC, and sarcoma with preliminary clinical data expected in the second half of 2025 and the first half of 2026. Preclinical studies of PYX-201 in combination with other agents in ovarian cancer and NSCLC to commence in 2025 to be followed by clinical studies with preliminary clinical data expected in 2026. PYX-201 demonstrated favorable preliminary tolerability profile data with low incidence of dose discontinuation, interruptions or delays due to treatment-related adverse events. Low incidence of Grade 3 or Grade 4 payload-related TRAEs within the identified dose range reinforce PYX-201's differentiated construct enabling enhanced molecular stability and differential expression of Extradomain-B in tumor tissue with negligible expression in normal tissues. The low incidence of Grade 1 or Grade 2 adverse events points to an attractive safety, given that it has been well tolerated and suitable for both monotherapy and combination therapy development. With respect to PK data, PYX-201 demonstrated increased stability in circulation, which we believe is due to its proprietary design of site-specific conjugation chemistry as compared to certain approved val-cit-monomethyl auristatin E ADCs with non-site-specific conjugation chemistry.

16:17 EST WesBanco raises quarterly dividend to 37c from 36c per share - WesBanco announced that its Board of Directors has approved a 2.8% increase in the quarterly cash dividend to 37c per common share from the previous quarterly dividend of 36c per common share. The higher dividend rate will be payable on January 2, 2025 to shareholders of record on December 6, 2024. This is the eighteenth increase in the quarterly dividend since 2010 and represents a cumulative increase of 164% over that period.

16:15 EST Karyopharm appoints Kristin Abate as Chief Accounting Officer - Karyopharm announced that Kristin Abate, the company's Vice President, Accounting, Corporate Controller and Assistant Treasurer, has been appointed Vice President, Chief Accounting Officer, and Assistant Treasurer, effective November 20. Abate, who has also served as interim principal financial officer and interim principal accounting officer since November 6, has been designated as the company's principal accounting officer, effective November 20, 2024. Abate will continue to serve as the company's interim principal financial officer. Abate has been employed by the company since July 2019 in a variety of roles with increasing seniority, most recently as its VP, Accounting, Corporate Controller and Assistant Treasurer. Prior to joining the company, Abate worked in various roles as a public accountant from 2007 to July 2019 at PricewaterhouseCoopers.

16:12 EST Snowflake raises FY25 product revenue view to $3.43B from $3.356B - Raises FY25 adjusted operating margin view to 5% from 3%.

16:11 EST Palo Alto Networks reports Q1 Next-Generation Security ARR $4.5B, up 40% y/y - Remaining performance obligation grew 20% year over year to $12.6B.

16:08 EST Snowflake to acquire open data integration platform Datavolo - Snowflake announced it has signed a definitive agreement to acquire Datavolo, the company built to rapidly accelerate the creation, management, and observability of multimodal data pipelines for enterprise AI. With this acquisition, Snowflake will deepen its service in the 'bronze layer' of the data lifecycle and will deliver a simple way for data engineering teams to integrate all of their enterprise systems with Snowflake's unified platform, where they can then unlock data for AI and ML, apps and analytics, and leverage the scale, performance, and built-in governance of the AI Data Cloud. Together, Datavolo and Snowflake will both simplify data engineering workloads and deliver unmatched data interoperability and extensibility - a building block for effective enterprise AI. "Simplicity and time-to-value are core to Snowflake's ethos. By bringing Datavolo into the Snowflake fold, we are expanding how much of the data lifecycle Snowflake captures - unlocking both simplicity and cost savings for our customers, without any sacrifice to data extensibility," said Sridhar Ramaswamy, CEO of Snowflake. "We are excited to have the Datavolo team join Snowflake as we accelerate what is the best platform for enterprise data - unstructured and structured, batch and streaming - and dedicated to the success of the open source community."

16:07 EST Snowflake raises FY25 product revenue view to $3.43B from $3.56B - Raises FY25 adjusted operating margin view to 5% from 3%.

16:07 EST Supermicro discloses Nasdaq compliance listing letter - The company states: "As previously announced, Super Micro submitted a compliance plan to Nasdaq on November 18, 2024 with respect to supporting its request for an extension of time to regain compliance with the Nasdaq continued listing requirements. In the compliance plan, the Company indicated that it believes it will be able to file both its Annual Report on Form 10-K for the fiscal year ended June 30, 2024 and its Quarterly Report on Form 10-Q for the period ended September 30, 2024, and become current with its periodic filings within the discretionary period available to the Nasdaq staff to grant. Consistent with prior announcements, and in accordance with Nasdaq marketplace rules, the Company today announced that the Company received a notification letter from Nasdaq stating that the Company is not in compliance with Nasdaq listing rule 5250(c)(1), which requires timely filing of reports with the U.S. Securities and Exchange Commission. The Letter was sent as a result of the Company's delay in filing its Q1 2025 Form 10-Q and its continued delay in filing its 2024 Form 10-K. The 2024 Form 10-K was due on August 29, 2024 and the Q1 2025 Form 10-Q was due on November 12, 2024. The Company filed Form 12b-25s regarding the 2024 Form 10-K and the Q1 2025 Form 10-Q on August 30, 2024 and November 13, 2024, respectively."

16:06 EST Crown reports Trump administration impact on Element 82, PE Pipelines segments - Crown Electrokinetics highlighted the potential impact of the incoming Trump administration on its lead pipe detection and remediation businesses, Element 82 and PE Pipelines. While many new EPA programs may face a regulatory freeze on January 20, 2025, the finalized LCRI legislation, effective December 30, will remain intact. The company said, "This stability ensures continued progress in identifying and replacing lead service lines nationwide. Further, the Trump administration is expected to prioritize critical water infrastructure challenges, including drinking water safety and lead pipe remediation. It was the 2016 Trump administration that revitalized the 1991 Lead and Copper Rule (LCR) laying the groundwork for the Lead and Copper Rule Revisions (LCRR) that were finalized in 2021. In order to support the strong demand for Crown's innovative solutions, the Company continues to explore all funding options including reinstating its Equity Line of Credit (ELOC) to ensure access to all forms of capital sources."

16:03 EST Nurix Therapeutics announces PRIME designation for NX-5948 from EMA - Nurix Therapeutics announced that the European Medicines Agency, or EMA, has granted PRIME designation for NX-5948, a highly selective degrader of Bruton's tyrosine kinase, for the treatment of adult patients with relapsed or refractory chronic lymphocytic leukemia or small lymphocytic lymphoma after at least a BTK inhibitor and a BCL-2 inhibitor. To be eligible for PRIME, medicines must target an unmet medical need and show potential benefit for patients based on early clinical data.

16:02 EST Amgen appoints Howard Chang as SVP of Research and Chief Scientific Officer - Amgen announced that Howard Chang will join the company as Senior VP of Research, effective Dec. 16. Chang will also assume the title and responsibility of serving as Amgen's Chief Scientific Officer, reporting to Jay Bradner, , EVP of Research and Development. Chang succeeds Ray Deshaies, former SVP of Research, whose departure was announced earlier this year.

15:47 EST SKK Holdings Ltd trading resumes

15:27 EST Eli Lilly and China-based biotech Laekna team on obesity drug - Earlier on Wednesday, Laekna, "a global biotech company focused on novel drug development for metabolic and cancer diseases," accoding to its release, announced a clinical collaboration with Eli Lilly and Company to accelerate the development of LAE102, a novel ActRIIA mAb as a novel treatment for obesity. Accelerating innovative treatments like this hopefully can make a meaningful impact on the obesity epidemic and the lives of millions of people affected by obesity... The collaboration will focus on the development and clinical evaluation of LAE102, an innovative ActRIIA antagonistic mAb that may have potential as a first-in-class therapy in this disease area. ActRIIA is a receptor that has been shown to play a critical role in muscle regeneration and lipid metabolism. LAE102 has been shown to both increase lean mass and decrease fat mass in pre-clinical models. If successful, LAE102 could, in combination with a GLP1R agonist, further reduce fat mass and significantly regain the lean mass loss induced by GLP1R agonist. This positions LAE102 as a promising complementary drug candidate for achieving quality weight control.By combining Laekna's novel approach with Lilly's decades-long experience in metabolic diseases, the partnership aims to significantly advance the standard of care in obesity management....Lilly will be utilizing Lilly's Catalyze360-ExploR&D engine to accelerate the development of LAE102.

15:18 EST Zeta Global Holdings trading resumes

15:05 EST Zeta Global issues 'detailed rebuttal' to 'false and misleading claims' - Zeta Global released a "detailed rebuttal" on its Investor Relations website that it says "debunks the assertions made in a self-serving short seller report published on November 13." "That 'report was riddled with misrepresentations, speculative conjecture, and categorically false statements about Zeta. The detailed rebuttal posted today builds on Zeta's initial response, also published on November 13," the company stated. David Steinberg, Co-Founder, Chairman, and CEO of Zeta, said, "The self-serving 'report' was filled with highly misleading and objectively false claims about Zeta and was written with a clear agenda: to drive down the value of our stock for the benefit of the author and the people betting against us. We, along with our external legal counsel, thoroughly reviewed its spurious allegations, and as we detail extensively in our rebuttal, the facts could not be clearer: our data gathering and management, privacy policies and practices, and financial reporting comply with relevant law and advance our mission of delivering value for our clients and generating shareholder value. As demonstrated by the Board's recent authorization of a $100 million stock repurchase program, and the purchases of Zeta stock by myself, and members of management and our board of directors, we have the utmost confidence in our business and Zeta's future. We've been able to use this dislocation in our stock price to buy back stock at an accelerated pace under our repurchase program, and we expect to continue to do so to further our value creation strategy. We will continue to communicate transparently with our stakeholders." View the rebuttal [here:]:[https://investors.zetaglobal.com/events-and-presentations/presentations/default.aspx. ]

14:56 EST Zeta Global Holdings trading halted, news pending

14:14 EST Uber announces UberX Share for the airport, new Uber Reserve features - In a blog post, Uber announced it is bringing UberX Share to the airport, providing travelers with a new, more affordable, hassle-free travel option. Now users can share their trip with just one other airport traveler and save up to 25% compared to their UberX fare, even if they're not matched with a co-rider. UberX Share at airports will be available Wednesdady in the U.S. at AUS (Austin), DEN (Denver), EWR (New York), IAD (Washington, D.C.), MIA (Miami), MSY (New Orleans), PHX (Phoenix), SFO (San Francisco), and internationally at AMS (Amsterdam) and MAD (Madrid) - with more to come. In addition, the company announces new Uber Reserve features. "With our new Flight Capture feature, riders can easily enter their flight details for a recommended best time to leave to help ensure a timely and stress-free airport arrival," the company said. "Our flight-tracking capability will alert riders if their flight gets delayed, and we'll ask them whether they want to adjust their airport drop off accordingly. Plus, riders can now add multiple stops when reserving a ride, perfect for picking up family, dropping off gifts, or making quick detours during the holiday rush." Reference Link

13:43 EST CD Projekt says 'no plans' for PS5 Pro patch for 'Cyberpunk 2077' - CD Projekt (OTGLY) said that it currently has no plans to release a PlayStation 5 Pro (SONY) patch for its game "Cyberpunk 2077." The game is currently available on standard PlayStation 5 consoles, PC, and Xbox Series X/S (MSFT). Reference Link

13:24 EST News Corp. says proposal to end dual-class capital structure defeated - News Corp announced that, at its annual meeting of stockholders, stockholders "overwhelmingly" elected the company's full slate of directors and voted with the board's recommendations on all proposals, including "convincingly defeating" the non-binding proposal to adopt a recapitalization plan that would eliminate News Corp's dual-class capital structure. "News Corp actively solicits feedback from its investors throughout the year, and values the ongoing dialogue generated by these extensive outreach efforts. We are pleased stockholders once again convincingly supported the company and the Board of Directors on all matters. Amidst a period of significant industry disruption, News Corp has thrived through a combination of smart organic reinvestment, strategic acquisitions and divestments and disciplined cost management programs. Under the leadership of the Board and executive team, the company has not only achieved record profitability-including a record Q1 in Fiscal 2025-but has also shifted to recurring and digital-first revenue streams, while continuing to create significant value for all stockholders. News Corp's success has been enabled in part by the current capital structure, and the company is pleased with the results of the Annual Meeting. News Corp's stock price has risen 45% over the past year, and materially outperformed both the S&P 500 and its designated peer group in recent years, but the company is by no means complacent. The Board and management are dedicated to driving sustained results, continuing the company's ongoing transformation and actively shaping the future of news and information in the AI era," the company stated.

13:02 EST U.K.'s CAT fines Pfizer, Flynn GBP 69M for excessive pricing after CMA probe - In a judgment handed down on Wednesday, the U.K.'s Competition Appeal Tribunal found that Pfizer and Flynn abused their dominant positions by charging excessive prices for a life-saving epilepsy drug, phenytoin sodium capsules, between 2012 and 2016. The CAT set aside the Competition and Market Authority's decision, but made its own infringement findings against the parties on 7 out of the 8 infringements originally found by the CMA. The CAT found that the parties intentionally abused their dominant positions and that "both Pfizer and Flynn were gouging the market in a manner that can only be characterized as unjustifiable or opportunistic or - in a word - unfair". The CAT went on to impose combined fines on Pfizer and Flynn of GBP 69M, almost identical to the fine levels imposed by the CMA. The CMA agrees with the CAT's conclusion that the firms' pricing behavior was abusive under competition law, and that significant fines are appropriate in this case. However, the CMA disagrees with the CAT's findings and reasoning in relation to the CMA's decision, and is carefully considering whether to appeal the judgment. In Wednesday's judgment, the CAT agreed with most of the drug firms' grounds of appeal, finding against the CMA in a number of matters, including in relation to the approach to calculating a 'reasonable rate of return', its assessment of unfairness, and the overall procedure followed. The CAT concluded that the firms had infringed the Chapter II prohibition. On the basis of those infringement findings, the CAT imposed the same level of fines as the CMA, but for a 1% reduction of Pfizer's fine. Reference Link

12:38 EST Supermajority of workers at Ford Kentucky plant sign union cards, says UAW - The United Auto Workers union said that a supermajority of workers at BlueOval SK in Kentucky have signed union authorization cards and today launched their public campaign to join the UAW. The campaign launch at BOSK, a joint venture of Ford and SK On, is the latest breakthrough for electric vehicle battery workers organizing with the UAW, the union said. The BOSK workers are building on the victories of UAW battery workers at Ultium Cells in Lordstown, Ohio, and Spring Hill, Tenn. Reference Link

12:02 EST Finance of America falls -17.2% - Finance of America is down -17.2%, or -$4.06 to $19.50.

12:02 EST Target falls -21.5% - Target is down -21.5%, or -$33.28 to $121.59.

12:00 EST Lemonade rises 15.8% - Lemonade is up 15.8%, or $6.35 to $46.49.

11:57 EST Square Enix says 'Final Fantasy XIV' coming to mobile - Square Enix announced that popular multiplayer online role-playing game "Final Fantasy XIV" will be coming to mobile devices. The company did not announce a launch date for the game. Reference Link

11:35 EST Elf Beauty slides after Muddy Waters goes short, questions revenue - Muddy Waters is short e.l.f. Beauty because the firm believes the company has "materially overstated revenue over the past three quarters - possibly by ~$135 million to ~$190 million." Carson Block's firm added: "We believe that in Q2 FY24, ELF management realized its growth narrative was in trouble as its inventory built. It appears that ELF then began reporting inflated revenue and profits. Its reported inventory also appears materially inflated as a result - i.e., to account for cash that has not really come in." The firm added in its short report: "ELF's claim it changed sourcing practices strikes us as categorically false. From speaking with a former China-side manager and three of ELF's largest suppliers, we understand that ELF's longstanding general practice was to take title to goods on the China side. Therefore, ELF's reported inventory build was seemingly due to insufficient sales - not a change in buying practices. This also strongly indicates that ELF was deceiving its auditor at that point (if not earlier), which is a major red flag." In late morning trading, Elf shares have fallen about 8% to $112.49. Reference Link

11:26 EST Goldman CEO says has not spoken directly with President-elect Trump - Goldman Sachs CEO David Solomon notes capital markets activity is picking up due to policy and sees more robust capital markets in 2025. Solomon says there are "gives and gets" in the new administration's expected policies, but overall the market is responding to the idea that the new administration will be more pro-growth. Solomon is being interviewed on CNBC.

11:04 EST TJX CEO says Q4 'off to a strong start' - Comments taken from Q3 earnings conference call.

10:28 EST Exicure Inc trading resumes

10:00 EST Sunnova Energy rises 12.2% - Sunnova Energy is up 12.2%, or 42c to $3.86.

10:00 EST Williams-Sonoma rises 23.2% - Williams-Sonoma is up 23.2%, or $31.82 to $169.06.

10:00 EST Fabrinet falls -10.8% - Fabrinet is down -10.8%, or -$26.78 to $221.96.

09:53 EST Delta Air Lines says has 'steady focus' on margin improvement - Expects to consistently deliver low single-digit non-fuel unit cost growth.

09:50 EST Lemonade rises 11.9% - Lemonade is up 11.9%, or $4.76 to $44.90.

09:48 EST Williams-Sonoma rises 24.5% - Williams-Sonoma is up 24.5%, or $33.63 to $170.87.

09:47 EST Fabrinet falls -10.0% - Fabrinet is down -10.0%, or -$24.95 to $223.79.

09:46 EST Danimer Scientific trading halted, volatility trading pause

09:37 EST Forte Biosciences trading resumes

09:33 EST EuroDry Ltd trading halted, volatility trading pause

09:30 EST Genprex signs exclusive license agreement with University of Michigan - Genprex announced it has entered into an exclusive license agreement with the University of Michigan, granting Genprex a worldwide, exclusive license to the University's patent rights relating toits lead drug candidate, Reqorsa Gene Therapy, or quaratusugene ozeplasmid, in combination with ALK-inhibitors for the potential treatment of ALK-EML4 positive translocated lung cancer. REQORSA in combination with ALK inhibitors could be a potential therapeutic treatment for ALK+ lung cancer. TUSC2 is a tumor suppressor gene that is frequently deleted in lung cancer. In fact, approximately 82% of all NSCLCs lack or express decreased amounts of TUSC2 tumor suppressor protein. ALK translocations are found in approximately 5% of NSCLCs. Research collaborators at the University of Michigan Rogel Cancer Center's Judith Tam ALK Lung Cancer Research Initiative presented positive preclinical data at the April 2024 American Association for Cancer Research, or AACR, Annual Meeting, reporting that REQORSA induced apoptosis in alectinib resistant EML4-ALK positive non-small cell lung cancer, or NSCLC, cell lines. The study found that the use of REQORSA or a TUSC2-containing plasmid to overexpress TUSC2 in ALK+ NSCLC cell lines was effective in decreasing cell growth and proliferation through the activation of apoptotic pathways. Researchers believe the results of this preclinical work support further clinical study of REQORSA as an anti-ALK NSCLC treatment strategy. Genprex believes this research suggests that REQORSA may be an effective treatment in patients progressing on ALK inhibitors.

09:27 EST Delta Air Lines sees continued demand strength, constructive industry backdrop - Says well-positioned for 2025. Sees "very encouraging" Q1. Says 15+ years of investment in product and service innovation has created an "unmatched position." Says premium products now producing highest margin "by far." Says premium products have a "significant runway." Says will explore additional segmentation in main cabin in 2025.

09:23 EST Connexa Sports announces correction to approval to continued listing on Nasdaq - Connexa Sports Technologies is announcing a correction to the third bullet point of the headline and the second paragraph of the press release published earlier today. In the Release, the third bullet point read: YYAI will commence trading at the opening of the market on Friday, November 22. and the second paragraph read: The new Connexa entity will continue to trade under the YYAI ticker symbol, with trading commencing at the opening of the market on Friday, November 22, 2024. Correction: "While we expect that November 22nd will be the first day of trading on a post-closing basis, we have not received confirmation of the first day of trading from Nasdaq yet. Connexa, as appropriate, will make further public announcements regarding the expected commencement of trading on a post-closing basis," the company said.

09:22 EST Mullen announces new orders for its Mullen ONE from California universities - Mullen Automotive announces new orders for its Mullen ONE, Class 1 commercial EV cargo van from two leading California universities in Los Angeles and Berkeley. This follows recent orders from prestigious higher education institutions across the nation like Princeton University in Princeton, New Jersey, University of Virginia, UVA, in Charlottesville, Virginia, and University of North Carolina, UNC, in Charlotte, North Carolina. The vehicles delivered in this announcement are through Mullen's commercial retail dealer partners, National Fleet Auto Group and Randy Marion Automotive Group.

09:19 EST Celanese and Henkel collaborate on adhesives made from captured CO2 emissions - Henkel Corporation and Celanese Corporation, a global chemical and specialty materials company, have announced a partnership to enhance circularity in emulsion production by utilizing carbon capture-based materials....Through this collaboration, Henkel will now produce water-based adhesives made from captured CO2 emissions, creating new opportunities for customers in the packaging and consumer goods sector to increase the renewable content of their products by keeping CO2 emissions in the production loop. As consumers and the market continue to demand products with lower environmental impact, these CCU-based adhesives will play a crucial role in driving sustainability across a wide range of applications. The Paper & Board, Envelopes & Graphic Arts, E-commerce, Labeling and Tissue & Towel industries can particularly benefit from CCU adhesives and the Henkel and Celanese partnership..."We are pleased to partner with Henkel to demonstrate another way in which Celanese ECO-CC products can support the transition to a more circular economy," said Kevin Norfleet, Global Sustainability Leader at Celanese. "Our CCU platform offers a compelling and scalable path to delivering sustainability into the adhesives market and we are continuing to work to develop solutions for a broad range of applications."

09:16 EST Palladyne AI and Red Cat expand partnership for Teal Drones - Palladyne AI (PDYN) announced an expanded partnership with Red Cat Holdings (RCAT) and its Teal Drones subsidiary , a drone technology company integrating robotic hardware and software for military, government, and commercial operations. The broadened relationship includes joint go-to-market activities to be coordinated between the companies..."We are extremely proud to be working with Teal on integrating our Palladyne Pilot artificial intelligence software into Teal's drones and look forward to this expanded relationship to help deliver a best-in-class experience for their defense, public safety, and commercial customers," said Ben Wolff, CEO, Palladyne AI. "Furthermore, we congratulate them on their selection as the winner of the U.S. Army's SRR Program of Record. This contract is extremely well-deserved as Teal sUAS systems exhibit superior capabilities across the board and particularly for complex military operations."

09:12 EST Planet Labs announces '6-figure deal' with Global Fishing Watch - Planet Labs PBC announced a new contract with Global Fishing Watch, an international nonprofit dedicated to advancing ocean governance through increased transparency of human activity at sea. The 6-figure deal is an expansion of the organization's ongoing agreement with Planet, and will allow Global Fishing Watch to fully leverage PlanetScope data and Machine Learning ML to improve ocean stewardship and foster greater compliance and accountability across all maritime sectors. The new contract represents a significant expansion of Global Fishing Watch's PlanetScope monitoring coverage, providing 3-meter optical imagery spanning most of the world's coastlines. With this heightened capability, Global Fishing Watch aims to map small vessel activity across millions of square kilometers of the ocean as far from the shoreline as possible. This will allow the organization to greatly augment its ability to detect small vessels that are not using Automatic Identification Systems AIS or Vessel Monitoring Systems VMS enabling more accurate determination of fishing activities and better support for ocean governance efforts around the world.

09:10 EST Daktronics amends, extends shareholder rights agreement - Daktronics announced that its Board of Directors has approved an amendment to the Company's existing Shareholder Rights Agreement, pursuant to which the expiration date of the Rights Agreement was extended to November 19, 2025, the exercise price was changed to $40.00, and the beneficial ownership threshold at which the rights become exercisable was changed to 15%.

09:10 EST Amazon says will not increase U.S. referral and FBA fees for 2025 - Dharmesh Mehta, Vice President, Worldwide Selling Partner Services at Amazon, stated in a corporate post: "Near the end of each year, we provide our selling partners with an update on the upcoming changes we are making to our referral and Fulfillment by Amazon - FBA - fees. These changes are designed to further enhance our partnership in serving customers, enable sellers to build thriving businesses, and create long-term value for sellers and our store. Looking back at 2024, we made a number of meaningful fee changes, including lowering our fulfillment fees for all low-priced products, lowering referral fees for low-priced apparel items, and evolving our fulfillment fee structure to separate inbound and outbound fees so we could provide sellers with more options that better align with our underlying costs... s we look to our 2025 seller fee changes, our focus is on continuing to partner together to delight customers and on providing our selling partners with a great value that helps their businesses thrive. After a year that had a number of fee changes for sellers to adapt to, for 2025, we are providing more stability in our fees so sellers can prioritize growing their businesses and leveraging our latest innovations. While we continue to see impacts from inflation and are making our biggest ever investment in pay and benefits for our fulfillment and transportation employees, we have also continued to invest in lowering our costs to serve. As a result, we are not introducing any new fee types or increasing referral or FBA fees, and we will decrease some fees and add new benefits to further support sellers and new selection growth." Reference Link

09:09 EST Bassett Furniture announces additional cost structure, workforce reductions - Bassett Furniture Industries announced certain work force reductions designed to both streamline operations and better match the Company's cost structure to the current rate of business. Through a combination of layoffs and retirements throughout the organization, this workforce reduction will result in approximately $2.5 million in annual savings. Including this action, Bassett has reduced its headcount by 11% over the past year. The Company expects to record an associated $500,000 severance charge in the current quarter. The Company further announced that it continues executing on its five-point restructuring plan announced on July 10, 2024 which is projected to provide between $5.5 million and $6.5 million of annual cost savings. Coupled with the work force reductions discussed above, annual savings are now projected to be between $8.0 million and $9.0 million.

09:07 EST CarParts.com announces new partnership with SimpleTire - CarParts.com announced its expansion into the tire market through a new partnership with SimpleTire. This launch introduces a robust selection of tire brands to CarParts.com, further enhancing its one-stop-shop experience for vehicle owners across North America. SimpleTire, one of the largest tire distributors in the country, offers a large catalog of 55 million tires from over 300 top brands, including trusted names like Pirelli, Yokohama, Continental, Hankook and Nexen. This diverse range ensures customers can find the right tires for a wide selection of vehicles, sizes, and performance needs, all at competitive prices.

09:05 EST Flywire appoints Jaques to board of directors - Flywire announces the appointment of Carleigh Jaques to its Board of Directors, effective immediately. Jaques will also serve as a member of the Audit Committee of Flywire's Board of Directors.

09:04 EST Ilustrato signs stock purchase agreement with Fusion Fuel Green - Ilustrato Pictures International recently signed a Stock Purchase Agreement with Fusion Fuel Green and certain other shareholders of Quality Industrial Corp. for Fusion Fuel to acquire a 69.36% stake in Quality Industrial. As consideration for the ILUS stake in QIND, Fusion Fuel will issue a combination of ordinary shares and convertible preferred shares, resulting in ILUS holding a stake of 55.38% of Fusion Fuel on an as-converted, fully diluted basis. The preferred shares, however, will not be converted until Fusion Fuel's shareholders approve their conversion to ordinary shares and clearance of an initial listing application to be filed with Nasdaq.

08:57 EST LPL Financial welcomes Strata Financial Group - LPL Financial announced that financial advisors Anthony Campagni, CFP, Ronald Jurczynski, CPA/PFS, Mitchell Romeo, CPWA, CPFA, Kyle Hancharick, CFP, and Dominic Elmo of Ohio-based Strata Financial Group have joined LPL Financial's broker-dealer, RIA and custodial platforms. The advisors join LPL from Osaic.

08:52 EST Target sees FY25 capital expenditures $4B-$5B - Says consumers remain pressured. Says beauty assortment continues to be a standout. Says expects to continue repurchasing shares in Q4. Says focused on planning business cautiously based on volatility experienced this year. Says sale and profit headwinds emerged in back half of the year. Says saw deceleration in apparel, but there are bright spots. Comments and guidance taken from Q3 earnings conference call.

08:49 EST Ally Financial announces several new leadership appointments - Ally Financial announced several new leadership appointments to further position the company for the future. Effective immediately, Stephanie Richard has been appointed Chief Risk Officer, responsible for execution of Ally's independent risk management. Throughout Richard's nearly 27-year tenure at Ally, she has served in numerous roles of increasing levels of responsibility within the finance, treasury and risk management functions, including chief audit executive and deputy chief risk officer. She has a long and respected reputation with key regulators and designed the company's risk appetite framework and stress testing process. Ally's prior Chief Risk Officer, Jason Schugel, will transition to an interim senior advisor role before leaving the company. Meghan Ryan has also been promoted to Chief Audit Executive, succeeding Richard. Ryan most recently served as CFO for Ally's Consumer and Commercial Banking businesses, and throughout her 13-year tenure with the company, she's held a variety of finance and treasury-related roles. Lindsay Sacknoff will join the company as head of Deposits and Invest, including Customer Care and Experience, effective January 13. In addition, Ali Summerville, Ally's business administration executive, has elected to leave the company. As part of the new structure, Kathie Patterson, Ally's Chief Human Resources officer, will assume responsibility for the Ally Charitable Foundation. Additionally, Sean Leary has been named Chief Financial Planning and investor relations officer, taking on additional responsibility for all business line CFO duties, continuing to report to Ally's CFO Russ Hutchinson.

08:39 EST Celularity strategic partner announces stem cell, regenerative medicine center - Celularity announced that its strategic partner, Genting Berhad, has broken ground on Fontaine Vitale, a stem cell and regenerative medicine facility in the Sanur Special Economic Zone located in Bali, Indonesia. Fontaine Vitale will offer world-class cell therapies focused on wellness, aesthetics, and regenerative medicine to both local and international patients using placenta-derived stem cells manufactured by Celularity in its US facility, according to Genting Berhad's press release. The new center is expected to commence commercial operations towards the end of 2026.

08:37 EST Dream Chasers Capital calls for 'urgent action' from Carver Bancorp CEO, board - Dream Chasers Capital Group called for urgent action from CEO Donald Felix and the board of directors of Carver Bancorp to drive growth and profitability at the company. Dream Chasers says the latest losses are more of the same. "The Board of Directors of a public company sets the plan, and the CEO executes it," said Greg Lewis, CEO of Dream Chasers Capital Group. "At Carver, every 'plan' the Board has set for the last ten years has only led to massive shareholder value destruction. For any team - whether a professional sports team or a company - such a losing record means new talent is necessary. Electing Mr. Anderson and Mr. Bailey to the Board gives Carver shareholders the best chance of success." Lewis continued, "I truly believe Carver's shareholders will be fortunate to have experienced and qualified directors in Jeff Anderson, the former CFO of J.P. Morgan's Northeast Region Retail Banking organization overseeing $100B in assets, and Jeff Bailey, a highly successful business owner and Carver's largest individual shareholder. As Directors, Mr. Anderson and Mr. Bailey will aggressively lead initiatives to make the bank profitable and increase shareholder value." Dream Chasers highlighted Carver's poor performance and the urgent need for change in a presentation filed with the SEC and sent shareholders a letter urging them to vote FOR Mr. Jeffrey "Jeff" Anderson and Mr. Jeffrey Bailey for election to the Board of Directors and vote WITHOLD on the Carver non-performing directors, using the BLUE proxy card. Reference Link

08:36 EST OSI Systems receives $11M order for electronic assemblies - OSI Systems announced that its Optoelectronics and Manufacturing division has received an order for approximately $11M to provide critical electronic sub-assemblies for a leading-edge healthcare original equipment manufacturer, OEM , known for innovative and specialized medical solutions. OSI Systems' Chairman and Chief Executive Officer, Deepak Chopra, stated, "We are pleased with this award from a leader in healthcare technology. This ongoing partnership highlights our commitment to quality and our ability to meet the needs of advanced medical technology providers."

08:34 EST EpicQuest announces Davis University agreement with Tokyo education center - EpicQuest Education Group International announced that Davis University recently entered into a Transfer Articulation Agreement with The Center of Advanced Studies, based in Tokyo, Japan, that operates international study programs in numerous schools in Southeast Asia and South America. The Agreement, effective December 1 establishes a pathway for international students from five Southeast Asian and South American colleges and universities to complete associate and bachelor's degrees in business at Davis University. "We believe that this Agreement can lead to a 20-25% increase in international student enrollment since it provides an excellent pathway for students from Southeast Asian countries to study in the US at Davis University," commented Diane Brunner, President of Davis University. The Agreement between Davis University ("Davis") and The Center for Advanced Studies, or CAS, establishes a transfer pathway by facilitating the transfer of credits for students from colleges and universities where CAS operates its International Studies Program to enroll in Davis' associate and bachelor's degree programs for business. International students from the CAS International Studies Program may start coming to Davis as soon as the Spring 2025 semester.

08:33 EST Nature's Miracle announces $2M debt to equity conversion - Nature's Miracle Holding announced that the company's management team and other debt holders have signed agreements to convert $2M of debt to equity at a price of 8.8c per share, the closing price at the end of November 19. To demonstrate alignment with shareholders, James Li, Chairman and CEO, is converting $577,000 of his personal loans into equity. Additionally, Jonathan Zhang, President, is converting the remaining outstanding trade payables due to Uninet Inc., a supplier to the company, into equity.

08:33 EST Volato provides update on path forward - The company said, "In the third quarter of 2024, Volato initiated the transition of its Fleet Operations to flyExclusive, with the transition anticipated to conclude in the fourth quarter of 2024. As part of this process, customer relationships, have been transferred from Volato to flyExclusive to ensure continuity and quality of service. This resulted in the reduction of Insider Card deposit liability of $4.1 million in the third quarter of 2024 and is expected to be even greater in the fourth quarter of 2024. As part of its turnaround, Volato is broadening the reach of its proprietary software, Mission Control, originally built specifically to support Volato's operations as a large-scale operator. Now chosen by one of the industry's largest operators, Mission Control has proven its flexibility and effectiveness in addressing varied operational needs. This choice over existing commercial software underscores a significant gap in the market-most available software doesn't meet the specialized requirements of large operators, leaving only a few with the capacity to create custom solutions. This adoption by a top-tier operator not only confirms Mission Control's adaptability but also serves as a proof of concept for broader industry use. Volato aims to extend Mission Control to other operators who need a strong, adaptable management solution, positioning it as a leading choice in aviation software."

08:32 EST Comscore awarded U.S. patent for person-level TV audience measurement - Comscore has been granted its patent on Personifying Viewership Data which allows marketers to understand person level viewership of linear or connected TV-including co-viewing-by using predictive modeling based on massive samples of passively-collected household-level data. This new capability, already integrated into Comscore's digital video, cross-platform, and TV solutions, provides more accurate insights into viewer demographics by leveraging Big Data viewing sources rather than only using costly panels with more sparse samples. It provides marketers with a privacy-forward way to measure exposure at the person level, while still benefiting from the scale of big data.

08:32 EST Cellebrite, Relativity deliver solutions to transform mobile data collection - Cellebrite and Relativity announced the general availability of the integration of Cellebrite's mobile collection solutions, Endpoint Inspector and Endpoint Mobile Now, into the RelativityOne platform.

08:17 EST Duos Technologies Group signs $42M asset management agreement with Fortress - Duos Technologies Group announces that its operating subsidiary Duos Energy Corporation has signed a two-year Asset Management Agreement, AMA, to deploy and operate a fleet of mobile gas turbines and balance-of-plant inventory that has a combined generation capacity of 850 megawatts. The AMA has been signed with affiliates of Fortress Investment Group; funds managed by affiliates of Fortress are acquiring the portfolio from APR Energy. Through the AMA, Duos will oversee the management and deployment of the assets. "This new agreement accelerates the diversification of Duos's business," said Chuck Ferry, CEO of Duos Technologies Group. "We are thrilled to partner with Fortress on deployment of the APR Energy assets. With rising demand across the globe for power generation, we see significant opportunity to deploy these high-capacity mobile turbines both in the US and internationally - and they're available immediately."

08:15 EST Organovo announces oral presentation of FXR314 - Organovo announces that its oral presentation of its lead clinical stage drug FXR314 by Dr. Eric Lawitz of the Texas Liver Institute and the University of Texas Health San Antonio was featured at The Liver Meeting, sponsored by the American Association for the Study of Liver Diseases, AASLD. The meeting was held November 15-19, 2024 in San Diego, California. The presentation entitled "Pharmacokinetics, Safety and Efficacy of the Novel Non-bile Acid FXR Agonist FXR314 in Patients with Metabolic Dysfunction-Associated Steatohepatitis: Results from a Phase 2 Study" was presented on Sunday, November 17 in the MASLD and MASH - New therapies session. Study subjects receiving FXR314 achieved statistically significant reduction in liver fat content from baseline, with LS mean percent reduction at end of treatment of 22.8% with 3 mg and 17.5% with 6 mg doses of FXR314 compared to 6.1% in the placebo group. FXR314 was also found to be safe and well tolerated. Treatment-emergent adverse events were mostly mild to moderate in severity, with incidence comparable between FXR314 3 mg, 6 mg, and placebo.

08:13 EST Xometry continues rapid expansion of global supplier base - Xometry announced that its global custom-manufacturing marketplace has more than 4,200 active suppliers, an increase of more than 780, or 34%, in the first three quarters of 2024, a nearly three-fold increase since 2021. The continued growth of active suppliers reflects the ability of Xometry's sourcing algorithms to provide suppliers with opportunities to profitably grow their business. Additionally, the Xometry Instant Quoting Engine is accessible in 16 local languages and accepts multiple currencies, making it simple for suppliers to join and conduct business worldwide.

08:12 EST Playtika completes strategic acquisition of SuperPlay - Playtika Holding has completed the acquisition of SuperPlay, a mobile gaming company based in Tel Aviv, Israel and home to hit mobile games Dice Dreams and Domino Dreams. "Acquiring SuperPlay is a strategic decision that underscores Playtika's mobile gaming industry leadership," said Craig Abrahams, Chief Financial Officer of Playtika. "SuperPlay diversifies our portfolio with proven titles, strengthens our competitive edge in an ever-evolving market and drives value for our shareholders."

08:10 EST Chipotle expects to open 315-345 new restaurants in 2025 - Chipotle is building a real estate pipeline that will allow it to accelerate new unit growth to be in the range of 8% to 10% per year, with the majority of new restaurants featuring a Chipotlane. The company is on track to open between 285 to 315 new restaurants this year, which marks record growth for the business. In 2025, Chipotle anticipates opening between 315 to 345 new restaurants with at least 80% including a Chipotlane.

08:08 EST Comcast announces intention to spin off NBCUniversal cable networks - Comcast announced its intent to create a new publicly traded company comprised of a portfolio of NBCUniversal's cable television networks, including USA Network, CNBC, MSNBC, Oxygen, E!, SYFY and Golf Channel along with digital assets including Fandango and Rotten Tomatoes, GolfNow and Sports Engine, through a tax-free spin-off. The independent company, or SpinCo, will have significant scale as a pure-play set of assets anchored by news, sports and entertainment content. SpinCo's stable of brands will provide a content offering that will reach approximately 70M U.S. households. The planned spin-off will also position NBCUniversal with its broadcast and streaming media properties, including NBC entertainment, sports, news and Bravo - which all power Peacock - along with Telemundo, the theme parks business and film and television studios. Mark Lazarus, current chairman of NBCUniversal Media Group, will serve as the company's CEO, and Anand Kini, current CFO of NBCUniversal and EVP of corporate strategy at Comcast, as its CFO and COO. Together they will lead the development of an independent strategy, while also establishing SpinCo as a potential partner and acquirer of other complementary media businesses. Over the last twelve months ended September 30, SpinCo generated approximately $7B in revenue. SpinCo will have the same dual-class share structure as Comcast. While SpinCo will operate as an independent business, it will enter into a transition services agreement with NBCUniversal to allow SpinCo to operate from day one. Comcast is targeting to complete the spin-off in approximately one year, subject to the satisfaction of customary conditions, including obtaining final approval from the Comcast board of directors, satisfactory completion of SpinCo financing, receipt of tax opinions and receipt of any regulatory approvals. There can be no assurance that a separation transaction will occur, or, if one does occur, of its terms or timing.

08:08 EST CME Group and LPGA announce extension of the CME Group Tour Championship - The Ladies Professional Golf Association, or LPGA, and CME Group, announced an extension of the CME Group Tour Championship and the season-long Race to the CME Globe through 2027. Since assuming title sponsorship of the LPGA Tour's season-ending tournament in 2011, CME Group has consistently grown its support, becoming one of the world's most prominent sponsors of women's sports. This title extension is yet another demonstration of CME Group's long-standing support for LPGA Tour athletes. The 2024 CME Group Tour Championship will feature an enhanced total purse of $11M, including a historic $4M first-place prize, the largest single prize in the history of women's golf. The runner-up will receive $1M. As part of its on-site footprint, CME Group will host its clients at the second annual Financial Face-off, a primary element of the week's pro-am experience. Today, 24 teams representing some of the world's leading companies will take to Tiburon Golf Club for 18 holes, playing alongside the LPGA Tour professionals from the CME Group Tour Championship field.

08:07 EST Comcast announces intention to spin off NBCUniversal television networks - Comcast announced its intent to create a new publicly traded company comprised of a portfolio of NBCUniversal's cable television networks, including USA Network, CNBC, MSNBC, Oxygen, E!, SYFY and Golf Channel along with digital assets including Fandango and Rotten Tomatoes, GolfNow and Sports Engine, through a tax-free spin-off. The independent company, or SpinCo, will have significant scale as a pure-play set of assets anchored by news, sports and entertainment content. SpinCo's stable of brands will provide a content offering that will reach approximately 70M U.S. households. The planned spin-off will also position NBCUniversal with its broadcast and streaming media properties, including NBC entertainment, sports, news and Bravo - which all power Peacock - along with Telemundo, the theme parks business and film and television studios. Mark Lazarus, current chairman of NBCUniversal Media Group, will serve as the company's CEO, and Anand Kini, current CFO of NBCUniversal and EVP of corporate strategy at Comcast, as its CFO and COO. Together they will lead the development of an independent strategy, while also establishing SpinCo as a potential partner and acquirer of other complementary media businesses. Over the last twelve months ended September 30, SpinCo generated approximately $7B in revenue. SpinCo will have the same dual-class share structure as Comcast. While SpinCo will operate as an independent business, it will enter into a transition services agreement with NBCUniversal to allow SpinCo to operate from day one. Comcast is targeting to complete the spin-off in approximately one year, subject to the satisfaction of customary conditions, including obtaining final approval from the Comcast board of directors, satisfactory completion of SpinCo financing, receipt of tax opinions and receipt of any regulatory approvals. There can be no assurance that a separation transaction will occur, or, if one does occur, of its terms or timing.

08:06 EST Stingray Group launches seven new free ad-supported streaming TV channels - Stingray announced the launch of seven new free ad-supported streaming TV channels now available for Xfinity customers to enjoy on X1 and the Xfinity Stream app. The lineup includes Stingray Naturescape and Stingray Holidayscapes. Additionally, five vibrant Stingray Music audio channels have launched, each catering to a wide range of musical tastes and preferences, enhancing the entertainment experience for Xfinity customers.

08:05 EST Aspen Technology board forms special committee to consider Emerson proposal - Aspen Technology (AZPN) announced that its Board of Directors has formed a special committee composed of three independent directors to consider the non-binding proposal from Emerson Electric (EMR) received on November 5 . Emerson and its affiliates currently own 57.4% of the company's outstanding common shares. The Special Committee is composed of Board Chair Robert Whelan, Jr., who will serve as Chair of the Special Committee, Arlen Shenkman and David Henshall. Qatalyst Partners and Citi are serving as independent financial advisors to the Special Committee and Skadden, Arps, Slate, Meagher & Flom LLP is serving as its legal counsel in connection with its review and evaluation of the proposed transaction. The Company reiterates that no action is required by its shareholders at this time.

08:04 EST Damon sees investment opportunities with California ZEM mandates - Damon announced it is poised to capitalize on California's newly introduced Zero-Emission Motorcycle, or ZEM, mandates, creating new revenue stream opportunities that Damon believes will solidify its position as a trailblazer in the motorcycle industry. Following the success of California's Zero Emission Vehicle, or ZEV, program, the state's zero emission mandates are now being expanded to the motorcycle industry with the ZEM program. The ZEM program aims to accelerate the transition to clean energy motorcycles by incentivizing manufacturers to exceed emission standards and rewarding those that lead the charge in sustainable innovation. Under the ZEV program, automakers that surpassed emission requirements were able to generate surplus credits, which they could then sell to companies struggling to meet the standards.

08:01 EST Comcast announces plan to spin-off of select cable television networks

07:53 EST Tesla Chairman Robyn Denholm sells $35.34M of shares - Tesla Chairman of the Board Robyn Denholm disclosed last night the sale of 112,390 shares at an average price of $314.44, for total proceeds of $35.34M. Denholm continues to own 85,000 shares of Tesla.

07:39 EST Dragonfly Energy announces publication of ESG report - Dragonfly Energy announced the publication of its inaugural Environmental, Social, and Governance, ESG, report. This comprehensive report underscores the Company's commitment to sustainability, diversity, equity, and inclusion, as well as its dedication to fostering a positive impact on the environment and communities it serves. Key Highlights from the 2023/2024 ESG Report: Sustainable Battery Cell Manufacturing; Non-Toxic Battery Pack Products; Workforce Development and Diversity; Community Engagement; Ethical Business Practices

07:38 EST Gulf Resources issues press release related to acquisition of salf fields - Gulf Resources issued a press release related to the purchase of additional land for salt fields and bromine. The Company believes that acquiring these salt fields will allow the Company to increase crude salt production and drill additional bromine wells. In evaluating these acquisitions, management calculated that the cash-on-cash returns may provide a payback within the next four to five years, which they consider a strong return on Investment. Liu Xiaobin, the Chief Executive Officer of Gulf Resources stated, "When we considered these acquisitions earlier this year, we were fully aware of their impact on our balance sheet. However, given our belief that Chinese economy is starting to recover, we saw this as a good investment."

07:36 EST Aptose Biosciences initiates TUSCANY Phase 1/2 study - Aptose Biosciences announced initiation of the TUSCANY study, tuspetinib, TUS, in combination therapy with azacitidine, AZA, and venetoclax, VEN, as a frontline triplet combination therapy for patients newly diagnosed with acute myeloid leukemia, or AML. The trial is being conducted at multiple U.S. clinical sites. "Initiation of the trial is a key milestone for Aptose. AML treatment has rapidly shifted to combination therapies, and we are pleased to include tuspetinib as part of TUS+VEN+AZA triplet combination therapy in patients with newly-diagnosed AML - representing a new patient population for TUS," said William G. Rice, Chairman, President and Chief Executive Officer. "We thank our investigators for their enthusiasm and our clinical team for activating the TUSCANY triplet study. As one of our investigators noted, if TUS brings added efficacy to frontline treatment of a broad array of AML patients without the added toxicities that are plaguing some other agents, we may have a game changer in TUS."

07:34 EST Mawson Infrastructure reports October revenue $4.89M - Total Monthly Revenue up 49% Y/Y from October 2023 and up 18% M/M from September 2024 to about $4.89 million. Energy Management Monthly Business Revenue was $0.70 million, up 13% M/M from September 2024 and Self-mining Digital Assets Mining Monthly Business Revenue was $0.22 million, up 25% M/M from September 2024. Digital Colocation Monthly Business Revenue was $3.96 million, up multi-fold Y/Y from $0.08 million in October 2023 and up 18% M/M from September 2024. Rahul Mewawalla, CEO and President said, "We are pleased to deliver another month of strong growth across our business with our total monthly revenue increasing 49% year-over-year and 18% month-over-month. We continue to advance our innovative approach to providing digital infrastructure platforms and solutions. Our synergistic business portfolio and our enhanced strategic, operational, and technological capabilities across all our businesses provides us with an exciting set of opportunities ahead."

07:32 EST 23andMe, Mirador enter strategic research collaboration - 23andMe and Mirador Therapeutics announced a strategic research collaboration. Under the agreement, Mirador will leverage a targeted set of aggregated, de-identified genetic and phenotypic data from the 23andMe research database and its proprietary Mirador360 development engine to enable target validation and precision medicine. "Mirador is a pioneer in I&I precision medicine, and our collaboration harnesses the power of 23andMe's data and research platform to identify new targets and develop promising new drugs," said Anne Wojcicki, CEO and Co-Founder of 23andMe. "We hope this can ultimately help the millions of patients living with a range of I&I diseases who urgently need treatment options."

07:31 EST Psyence announces favorable result on Nasdaq listing qualifications hearing - Psyence Biomedical announced the favorable outcome of the Nasdaq Listing Qualifications Hearing that was held on October 31st, 2024. The Nasdaq Hearings Panel has granted Psyence Biomed an extension until December 31st, 2024, to demonstrate compliance with all Nasdaq continued listing rules.

07:23 EST Pasithea Therapeutics announces SRC recommended proceeding to cohort 4 - Pasithea Therapeutics announced that the external Safety Review Committee, SRC, recommended proceeding to cohort 4, 15mg capsule, without modifications. This recommendation was based on the absence of any dose limiting toxicities, DLTs. In addition, no rash was observed in any of the first 9 patients who received PAS-004. The Company has decided to add a cohort 4b to the trial, which will consist of 3 additional patients and introduce an alternate formulation which is intended for commercial use.

07:21 EST Cytomed Therapeutics announces first patient dosed in ANGELICA Trial - CytoMed Therapeutics announces that the first patient has been dosed in its first-in-human Phase I dose-escalation clinical trial, ANGELICA trial. This trial has been registered with and has received clinical trial authorization from the Health Sciences Authority in Singapore. The ANGELICA Trial evaluates allogeneic NKG2DL-targeting chimeric antigen receptor-grafted gamma delta T cells in patients with advanced solid tumours or haematological malignancies. Refer to Form 6K announcement on October 7, 2024. "Dosing the first patient in the ANGELICA Trial, CytoMed has reached a significant milestone as a clinical stage biopharma," says Chairman Peter Choo. "The ANGELICA Trial aims to assess the safety and potential efficacy of an allogeneic CAR-T therapy patients with advanced solid tumours or haematological malignancies."

07:16 EST Former Harrow unit Melt announces results for MELT-300 to sedate for surgery - Melt Pharmaceuticals announced positive topline results of its pivotal Phase 3 study evaluating the safety and efficacy of its lead product candidate, MELT-300, a non-IV, non-opioid tablet for procedural sedation during cataract surgery. Based on a Special Protocol Assessment agreement reached with the U.S. Food and Drug Administration earlier this year, this study design and these positive results support the necessary objectives required for a regulatory submission. George Magrath, M.D., a board-certified ophthalmologist and a MELT-300 Phase 3 study principal investigator, commented...In commenting on the topline results, Dr. Larry Dillaha, Chief Executive Officer of Melt, said, "We are extremely excited with this robust topline data from our pivotal Phase 3 study. These overwhelmingly positive results support our belief that MELT-300, if approved by the FDA, would be a safe and effective non-IV, non-opioid alternative to current IV-based cataract surgery sedation protocols, which generally involve the administration of opioids. With the number of cataract surgeries performed each year in the U.S. expected to exceed 5 million in the coming years, we believe offering patients and physicians the ability to achieve an adequate sedation level without the need to start an IV or administer opioids is a very attractive proposition."

07:14 EST Recursion, Exscientia officially combine to advance drug discovery - Recursion (RXRX) and Exscientia has been completed, with Exscientia becoming a wholly owned subsidiary of Recursion creating a vertically-integrated and technology-enabled drug discovery platform. Exscientia ADSs (EXAI) ceased trading and will be delisted from Nasdaq. "I believe the combination of the incredible teams and platforms at Exscientia and Recursion position us as the leader of the AI-enabled drug discovery and development space," said Chris Gibson, Ph.D., Co-Founder and CEO of Recursion. "With more than 10 clinical and preclinical programs in the internal pipeline, more than 10 partnered programs and over $450M in upfront and realized milestone payments received from partners to date out of more than $20B possible, we are advancing a flywheel of discovery and creating value in our pipeline through technology."

07:12 EST LuxUrban Hotels reports Q3 net rental revenue $13.1M vs $31.2M last year - Gross (Loss) Profit: $(16.8) million, compared to a profit of $7.8 million in Q3 2023; Total Operating Expenses: $12.1 million, compared to $2.7 million in Q3 2023, reflecting $9.7 million reserve for litigation with landlords;Net Loss: $30.7 million, compared to a net income of $4.9 million in Q3 2023. Rob Arigo, LuxUrban Hotels CEO, commented: "As we close out 2024 and enter 2025, we are excited to build on our LuxUrban 2.0 initiative. This strategy not only focuses on the elimination of non-performing hotel properties but also reinforces our commitment to enhancing operational efficiency. We have strengthened our management team by bringing on talented directors and officers with deep expertise in the hospitality and financial sectors. While challenges remain as we continue to transition from, and address obligations related to, legacy operations, we believe that the transformative changes we are implementing will enhance our financial stability and set a solid foundation for future growth. We look forward to updating our shareholders as we advance on this path and capitalize on the opportunities ahead."

07:08 EST Solaris announces final steps to complete emigration, appoints Rowlinson as CEO - Solaris Resources (SLSR) announce the final steps to complete its emigration by year-end following the Company's previous announcement to position the Company to maximize returns for shareholders and protect the interests of stakeholders by aligning with regulators in Ecuador as Warintza completes the permitting process. In connection with the emigration, the Company announces the appointment of Matthew Rowlinson as President and Chief Executive Officer of the Company, effective January 1, 2025, to be based in a new office in Zug, Switzerland, with further appointments in this office to follow. Rowlinson most recently served as the Head of Copper Business Development for Glencore (GLNCY). The Company is also pleased to announce the appointment of Mr. Matthew Rowlinson, Mr. Rodrigo Borja, and Mr. Hans Wick to the Company's board of directors effective January 1, 2025. The Company's directors in Canada, Mr. Daniel Earle, Ms. Poonam Puri, Mr. Kevin Thomson and Mr. Ron Walsh will resign from their roles on the board effective January 1, 2025.

07:07 EST Acurx board approves Bitcoin as treasury reserve asset - Acurx Pharmaceuticals announced that the company's Board of Directors approved the purchase of up to $1M in Bitcoin to hold as a treasury reserve asset. "As demand for Bitcoin grows, and so does its acceptance as a major and primary asset class, we believe that Bitcoin will serve as a strong treasury reserve asset for cash not needed over the next 12 to 18 months" said David Luci, President & CEO of Acurx. "With the recent approval of Bitcoin ETFs and the growing support from government agencies and institutional investors, it is a great addition to our treasury strategy. Its limited supply and inflation-resistant characteristics provide a functional store of value. This new treasury strategy is a finance strategy and has no impact on our overarching drug development plans."

07:05 EST Vitalhub announces SHREWD implementation with WRHA - Vitalhub announces that it has successfully completed an implementation of its regional patient flow and whole-system visibility platform, SHREWD, to support improved patient flow and safer, more effective care coordination. SHREWD is a real-time operational management platform which supports - and gathers data from - hospitals, long-term care facilities, community & cancer care services, inter-facility transport services, ambulance and paramedic services, and telehealth services. SHREWD is enabling the Winnipeg Regional Health Authority, WRHA, to leverage data from a wide variety of disparate information systems across the health network, aggregated to provide them with visibility of system pressures at a glance.

07:02 EST C4 Therapeutics appoints Hoerter to board of directors - C4 Therapeutics announced the continued evolution of its Board of Directors with the appointment of Steve Hoerter as a director.

07:01 EST Methode Electronics appoints Ullrich as SVP, Global Automotive Business - Methode Electronics announced today that Lars Ullrich has been appointed as Senior Vice President,SVP, Global Automotive Business, effective December 2, 2024. The newly created position will oversee all global strategic, launch, and commercial activities for the company's automotive business.

06:46 EST Pfizer confirms Chris Boshoff as chief scientific officer - Pfizer announced that after a comprehensive internal and external selection process, the company is appointing Chris Boshoff, M.D., PhD, as Chief Scientific Officer and President, Research & Development effective January 1, 2025. Dr. Boshoff, who most recently served as Chief Oncology Officer and Executive Vice President, will succeed Dr. Mikael Dolsten whose departure from Pfizer was announced earlier this year. In his new role, Dr. Boshoff will remain a member of Pfizer's Executive Leadership Team reporting to Chairman and Chief Executive Officer, Dr. Albert Bourla, and he will oversee all functions of Research & Development across all therapeutic areas. Pfizer's Oncology R&D organization will maintain its fully integrated structure with Roger Dansey, M.D. serving as Interim Chief Oncology Officer, reporting to Dr. Boshoff effective January 1, 2025. Dr. Dansey will assist Dr. Boshoff in selecting a permanent Chief Oncology Officer, after which time he will retire from Pfizer. He will also facilitate a smooth transition of his current responsibilities to his successor, Johanna Bendell, M.D. who will be joining Pfizer from Roche in 2025 as Chief Development Officer, Oncology.

06:37 EST Target sinks 19% to $126.99 after Q3 miss, guidance cut

06:31 EST Sage Therapeutics reports results from Phase 2 DIMENSION Study - Sage Therapeutics announced topline results from the Phase 2 DIMENSION Study of dalzanemdor, or SAGE-718, in participants with cognitive impairment, or CI, associated with Huntington's Disease, or HD. In the study, dalzanemdor did not demonstrate a statistically significant difference versus placebo on the primary endpoint, the change from baseline on the Symbol Digit Modalities Test, or SDMT, at Day 84. Analyses of secondary endpoints did not demonstrate statistically significant or clinically meaningful differences in participants treated with dalzanemdor compared to placebo. Based on these results, the Company does not plan further development of dalzanemdor. The DIMENSION Study was a 12-week, double-blind, placebo-controlled Phase 2 study to evaluate the effects of dalzanemdor in participants with CI associated with HD. A total of 189 participants were randomized. The DIMENSION Study did not demonstrate a statistically significant difference from baseline in participants treated with dalzanemdor versus placebo on the SDMT, a measure of cognitive function, at Day 84, the primary endpoint. Dalzanemdor was generally well-tolerated and no new safety signals were observed. The majority of treatment emergent adverse events were mild to moderate in severity. Analyses of secondary endpoints did not demonstrate statistically significant or clinically meaningful differences between the dalzanemdor and placebo treatment groups. Given these findings, the Company also will close the ongoing PURVIEW Study, an open-label safety study of dalzanemdor in participants with HD.

06:22 EST Tutor Perini announces $100M debt paydown - Tutor Perini announced that the company has pre-paid an additional $100M of its Term Loan B debt. Building on the paydown of $50M of the Term Loan B debt that was disclosed in the company's November 6 earnings release, Tutor Perini has now successfully deleveraged its balance sheet by $150M in the last month, representing the upper end of its targeted debt reduction plan for the fourth quarter of 2024. As of November 20, the remaining principal balance of the Term Loan B, after these recent paydowns, was approximately $123M. The company recently disclosed plans to pay down an additional $50M-$75M of the Term Loan B debt in the first quarter of 2025, and it now expects to pay down an amount that exceeds the upper end of this range. All the debt repayments mentioned above represent voluntary, early paydowns of the Term Loan B debt.

06:07 EST Comstock executes existing binding agreement with SACL - Comstock announced execution of a binding amendment to an existing agreement between Comstock Fuels and SACL, a Singapore-based renewable fuel project developer, under which Comstock Fuels agreed to grant SACL an exclusive marketing agreement for Comstock Fuels' advanced lignocellulosic biomass refining processes in Vietnam. The amendment was executed to increase SACL's territory to facilitate the financing, construction, and operation of SACL's first planned site in Vietnam, in addition to three existing sites currently under development in Australia, now totaling over 460M gallons of renewable fuels, with an emphasis on sustainable aviation fuel, or SAF. SACL and its stakeholders previously identified three qualified sites for the construction of three Bioleum Refineries based on Comstock Fuels' industry leading yields and decarbonizing impact, including a 250,000 metric ton per year, or MTPY, refinery located near Portland, Victoria, Australia, a 250,000 MTPY refinery located near Moree, New South Wales, Australia, and a 750,000 MTPY refinery located near Mackay, Queensland, Australia. However, SACL is actively evaluating additional projects for development in the Pacific Rim, including SACL's now-planned new 750,000 MTPY Bioleum Refinery in Quang Tri Province, Vietnam. Under the terms of Comstock Fuels' agreement with SACL, Comstock Fuels will contribute site specific technology rights in exchange for a 20% equity stake in each Bioleum Refinery, plus a royalty fee equal to 6% of each refinery's sales of licensed products, and engineering fees equal to 6% of total construction costs. At least one of the Bioleum Refineries will initially start with a capacity of 75,000 MTPY. Together, all four Bioleum Refineries will have an estimated total construction cost of over $4.0B and produce approximately 280M gasoline gallon equivalent basis, or GGE, of sustainable aviation fuel, and other renewable fuels from lignocellulosic biomass, and about another 180M GGE from vegetable oils, with over $3.0B per year in sales at current prices.

06:05 EST Argenx to continue development of efgartigimod subcutaneous - Argenx announced the decision to continue development of efgartigimod subcutaneous in the ongoing Phase 2/3 ALKIVIA study in adults with idiopathic inflammatory myopathies, following analysis of topline data from the Phase 2 portion of the study. ALKIVIA will continue to enroll patients across each of the three myositis subtypes in the study, including immune-mediated necrotizing myopathy, anti-synthetase syndrome, and dermatomyositis. The decision to continue clinical development of efgartigimod SC in each of the three myositis subtypes is supported by the efficacy and safety results from the Phase 2 portion of the seamless Phase 2/3 ALKIVIA study. Overall, the study met its primary endpoint, demonstrating a statistically significant treatment effect in mean total improvement score at Week 24, and showed improvement across all six core set measures of the TIS in favor of efgartigimod SC compared to placebo. The observed safety and tolerability profile was consistent to that demonstrated with other clinical trials.

06:03 EST Exxon Mobil and LG Chem sign provision agreement for lithium carbonate - Exxon Mobil and LG Chem have signed a non-binding memorandum of understanding, or MOU, for a multiyear offtake agreement for up to 100,000 metric tons of lithium carbonate. The lithium will be supplied from ExxonMobil's planned project in the U.S. to LG Chem's cathode plant in Tennessee, which LG Chem expects to be the largest of its kind in the U.S. LG Chem's Tennessee cathode plant broke ground in December 2023 and is expected to have an annual production capacity of 60,000 tons. The plant offers excellent geographic accessibility for both customer deliveries and raw material imports. Final investment decision will be subject to various factors including the establishment of commercially competitive regulatory frameworks. The planned production of MobilTM Lithium will utilize Direct Lithium Extraction technology, aligning with ExxonMobil's competencies in subsurface exploration, drilling, and chemical processing.

05:51 EST Nokia awarded multi-year, multi-billion extension deal by Bharti Airtel - Nokia has been awarded a multi-year, multi-billion extension deal by Bharti Airtel to deploy 4G and 5G equipment across key Indian cities and states. As per the contract, Nokia will deploy equipment from its 5G AirScale portfolio including base stations, baseband units and the latest generation of Massive MIMO radios, all powered by its energy-efficient ReefShark System-on-Chip technology. These solutions will enhance Airtel's network with exceptional 5G capacity and coverage and support its network evolution. Furthermore, Nokia will modernize Airtel's existing 4G network with multiband radios and baseband equipment, which can also support 5G. Airtel will also be leveraging Nokia's MantaRay Network Management for intelligent network monitoring and management that uses AI-based tools covering digital deployment, optimization and technical support.

05:42 EST Pfizer announces EC approval for Hympavzi - Pfizer announced that the European Commission, or EC, has granted marketing authorization for Hympavzi for the routine prophylaxis of bleeding episodes in patients 12 years of age and older weighing at least 35 kg with severe hemophilia A without FVIII inhibitors or severe hemophilia B without FIX inhibitors. Hympavzi is the first and only anti-tissue factor pathway inhibitor approved in the European Union, or EU, for the treatment of hemophilia A or B and the first hemophilia medicine approved in the EU to be administered via a pre-filled, auto-injector pen. HYMPAVZI offers a subcutaneous treatment option with a once-weekly dosing schedule and minimal preparation required for each individual administration.

05:13 EST Canaan expands self-mining footprint in Texas, Pennsylvania - Canaan announced that its wholly owned subsidiary, Beet Digital, has entered into a strategic joint mining agreement with Luna Squares Texas, a West Texas Bitcoin mining firm, to collaborate on mining activities at LS Texas' mining site. The agreement is part of the company's plan to reach 10 exahash per second capacity in North America by mid-2025. Under the agreement, each party will be allocated a portion of the BTC revenue less electricity, maintenance, and operating costs. For revenue generated from Canaan's Avalon A14 Series, each party will receive 50%. For revenue generated from any Avalon A15 Series deployed to the site, to accelerate recovery of Canaan's capital costs, Canaan will be allocated 70% and LS Texas will receive 30%. After Canaan has recovered the capital cost of the machines, each party will again receive 50%.

05:06 EST Canaan secures follow-on order from Hive Digital for 5,000 Avalon miners - Canaan (CAN) announced that Canaan Creative, a wholly owned Singapore subsidiary of the company, has entered into a follow-on order purchase agreement with Hive Digital (HIVE), for its Avalon A15-194T miners. According to the purchase agreement, CCG will provide Hive with 5,000 Avalon A15-194T miners, with an average computing power of 194 Terahash per second, expected to be delivered in the first quarter of 2025.